-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] China is one of the largest pharmaceutical consumption markets in the wor.
In the past, most multinational pharmaceutical companies only regarded China as a marketing market or manufacturing ba.
But in recent years, with the rise of innovation in China, multinational pharmaceutical companies are gradually becoming a bridge for Chinese new drugs to go overse.
It is understood that under the industrial transformation set off by the new policies of the National Drug Administration, more and more multinational companies with strong commercialization capabilities and Chinese companies that are deeply involved in the research and development of local innovative drugs are joining forces to jointly promote the research and development of new drugs, listing and overse.
Reach patients quick.
For example, on August 5, Kelun Pharmaceutical announced that its holding subsidiary Kelun Botai will exclusively license its biological macromolecular tumor project A (SKB264) with independent intellectual property rights to MSD in May 202 Research, development, manufacturing and commercialization outside of China (China includes Mainland China, Hong Kong, Macau and Taiwa.
In fact, in July this year, Columbotech just announced that it has exclusively licensed its biological macromolecular tumor project B with independent intellectual property rights to MSD for global research, development, manufacturing and commercializati.
This cooperation means that the license out transaction of Kelun Pharmaceuticals will be another succe.
On July 28, CSPC announced that CSPC Jushi Bio, a subsidiary of CSPC, will join hands with Elevation, which will acquire CSPC Jushi Bio's innovative anti-Claudin12 antibody-drug conjugate SYSA1801 in Greater China (including Development and commercialization rights outside mainland China, Hong Kong, Macau and Taiwa.
It is reported that through this transaction, CSPC Jushi Bio will receive an upfront payment of US$27 million and has the right to receive potential development and regulatory milestone payments of up to US$148 million and potential sales milestone payments of up to US$02 billi.
In addition to the above-mentioned pharmaceutical companies, Hua Medicine and Bayer have established strategic cooperation on the glucokinase activator (GKA) diabetes treatment drug dozagliadi.
ADC) LM-302 reached an exclusive overseas licensing cooperation, and Hebo Pharmaceuticals licensed the company's new bispecific antibody HBM7022 generated by the company's HCAb-based immune cell adapter (HBICE) platform to AstraZeneca for development and commercializati.
The industry believes that, from the above point of view, the license-in model has become a "shortcut" for domestic innovative pharmaceutical companies to go overseas and overtake in curv.
It is understood that in recent years, the number and amount of domestic innovative drugs participating in license in transactions have actually continued to ri.
Among them, in the first half of 2021 alone, among the disclosed license in transactions of pharmaceutical companies, the transaction amount exceeded 100 million US dollars, which has approached 2
.
In general, with the advancement of new medical reform policies such as centralized procurement and generic drug consistency evaluation, Chinese pharmaceutical companies are accelerating their transformation from generic drugs to innovative drugs, with increasing R&D investment and increasing innovation streng.
In this context, the innovative strength of domestic pharmaceutical companies will be more and more recognized by multinational pharmaceutical companies; at the same time, multinational pharmaceutical companies will also become a bridge for more and more Chinese new drugs to go overseas, further enhancing the world influence of "intelligent manufacturing in Chin.
And benefit global patients with wider coverage and faster acce.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
In the past, most multinational pharmaceutical companies only regarded China as a marketing market or manufacturing ba.
But in recent years, with the rise of innovation in China, multinational pharmaceutical companies are gradually becoming a bridge for Chinese new drugs to go overse.
It is understood that under the industrial transformation set off by the new policies of the National Drug Administration, more and more multinational companies with strong commercialization capabilities and Chinese companies that are deeply involved in the research and development of local innovative drugs are joining forces to jointly promote the research and development of new drugs, listing and overse.
Reach patients quick.
For example, on August 5, Kelun Pharmaceutical announced that its holding subsidiary Kelun Botai will exclusively license its biological macromolecular tumor project A (SKB264) with independent intellectual property rights to MSD in May 202 Research, development, manufacturing and commercialization outside of China (China includes Mainland China, Hong Kong, Macau and Taiwa.
In fact, in July this year, Columbotech just announced that it has exclusively licensed its biological macromolecular tumor project B with independent intellectual property rights to MSD for global research, development, manufacturing and commercializati.
This cooperation means that the license out transaction of Kelun Pharmaceuticals will be another succe.
On July 28, CSPC announced that CSPC Jushi Bio, a subsidiary of CSPC, will join hands with Elevation, which will acquire CSPC Jushi Bio's innovative anti-Claudin12 antibody-drug conjugate SYSA1801 in Greater China (including Development and commercialization rights outside mainland China, Hong Kong, Macau and Taiwa.
It is reported that through this transaction, CSPC Jushi Bio will receive an upfront payment of US$27 million and has the right to receive potential development and regulatory milestone payments of up to US$148 million and potential sales milestone payments of up to US$02 billi.
In addition to the above-mentioned pharmaceutical companies, Hua Medicine and Bayer have established strategic cooperation on the glucokinase activator (GKA) diabetes treatment drug dozagliadi.
ADC) LM-302 reached an exclusive overseas licensing cooperation, and Hebo Pharmaceuticals licensed the company's new bispecific antibody HBM7022 generated by the company's HCAb-based immune cell adapter (HBICE) platform to AstraZeneca for development and commercializati.
The industry believes that, from the above point of view, the license-in model has become a "shortcut" for domestic innovative pharmaceutical companies to go overseas and overtake in curv.
It is understood that in recent years, the number and amount of domestic innovative drugs participating in license in transactions have actually continued to ri.
Among them, in the first half of 2021 alone, among the disclosed license in transactions of pharmaceutical companies, the transaction amount exceeded 100 million US dollars, which has approached 2
.
In general, with the advancement of new medical reform policies such as centralized procurement and generic drug consistency evaluation, Chinese pharmaceutical companies are accelerating their transformation from generic drugs to innovative drugs, with increasing R&D investment and increasing innovation streng.
In this context, the innovative strength of domestic pharmaceutical companies will be more and more recognized by multinational pharmaceutical companies; at the same time, multinational pharmaceutical companies will also become a bridge for more and more Chinese new drugs to go overseas, further enhancing the world influence of "intelligent manufacturing in Chin.
And benefit global patients with wider coverage and faster acce.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
